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ABSTRACT
In patients with obstructive jaundice, when the endoscopic approach fails to achieve biliary drainage, percu-
taneous cannulation and combined endoscopic/percutaneous endoprosthesis insertion can simultaneous-
ly or subsequently be performed. The present study compares these two approaches. endoscopic retrograde 
biliary drainage (erBd) and percutaneous transhepatic biliary drainage (PTBd) are the two main non-sur-
gical treatment options for obstructive jaundice in patients with hepatocellular carcinoma (HCC). erBd is 
usually the first-line treatment because of its low hemorrhage risk. some authors have reported that the suc-
cessful drainage rate ranges from 72 to 100%. Mean stent patency time and mean survival range from 1,0 
to 15,9 and from 2,8 to 12,3 months, respectively. PTBd is often an important second-line treatment when 
erBd is impossible. With regard to materials, metallic stents offer the benefit of longer patency than plastic 
stents. The dominant effect of biliary drainage suggests that successful jaundice therapy could enhance an-
ticancer treatment by increasing the life expectancy, decreasing the mortality, or both. We present an over-
view of the efficacy of erBd and PTBd for obstructive jaundice in HCC patients who are not candidates for 
surgical resection and summarize the current indications and outcomes of reported clinical use. Tradition-
ally, surgical techniques have been used, however, in the last 20 years the availability of both endoscopic and 
interventional radiological procedures has increased. Тhe technical success of the procedure depends on the 
experience of the interventional radiologist performing the drainage. It can be as high as nearly 100%. Clin-
ical efficacy is usually lower but still over 90%. When endoscopic drainage alone fails, a combined percuta-
neous/endoscopic procedure should only be performed if it can be carried out simultaneously.
Key words: biliary drainage, obstructive jaundice, percutaneous transhepatic biliary drainage, endoscopic 
retrograde biliary drainage, hepatocellular carcinoma
INTRODuCTION
Controversy exists concerning the preferred 
technique of percutaneous biliary drainage (PBD), 
either via endoscopic retrograde biliary drainage 
(ERBD) or by means of antegrade percutaneous 
transhepatic biliary drainage (PTBD) (42). PTBD 
is the preferred method in Japan for relief of 
obstructive jaundice due to proximal obstruction. 
In Europe and the USA, endoscopic biliary drainage 
(EBD) is usually performed as primary intervention 
and is followed by PTBD only when EBD has failed. 
Internal drainage by EBD, although a less invasive 
technique, carries increased risk of developing 
cholangitis due to bacterial contamination from the 
duodenum and increased risk of procedure-related 
complications such as duodenal perforation and 
post-EBD acute pancreatitis (12,22). Drainage by 
means of PTBD is associated with hemobilia, portal 
vein thrombosis, cancer seeding and potentially 
more patient’s discomfort (2). Three published 
prospective randomized controlled trials comparing 
EBD versus PTBD include patients with unresectable 
bile duct tumours or carcinoma of the gallbladder 
and pancreas showing conflicting results. These 
studies address palliative treatment and although 
important in the context of biliary drainage, no 
distinction is made between distal and proximal 
bile duct obstruction. In patients with HCC with 
involvement of the segmental biliary ducts, drainage 
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of the intrahepatic biliary tree is challenging and 
mostly requires multiple drains or stents. However, 
in patients with a distal bile duct obstruction, 
usually caused by a tumour in the region of the 
pancreatic head, drainage is more straightforward 
and requires a single drain or stent. In the latter 
category of jaundiced patients in whom partial liver 
resection is usually not undertaken, PBD remains a 
controversial issue (11). 
To date, there are no studies regarding 
the optimal route of drainage in patients with a 
potentially resectable HCC. Therefore, the aim of 
the present study is to compare the success rate and 
complications of ERBD and PTBD in patients eligible 
for resection of a suspected HCC.
Diagnostic percutaneous transhepatic 
cholangiography gradually develops into a technique, 
which allows prolonged external catheter drainage of 
malignant strictures in the biliary system (18). Further 
developments include percutaneous placement of 
multiple side-hole catheters into the duodenum, 
thereby establishing the internal bile drainage (28). 
Early series show a considerable number of infectious 
complications (approximately 40%), but further 
refinements produce better results (26). 
Percutaneous biliary drainage
The technique we currently routinely use 
involves the use of ultrasound guidance, a thin Chiba 
needle and a 0.014-inch guide-wire to gain access to 
the biliary system. A sheath is then placed over an 
0.35-inch guide-wire and strictures are negotiated 
using standard 5-French angiographic catheters and 
hydrophylic guide-wires. For permanent stenting 
self-expandable metallic stents are used. Metal self-
expandable stents are the standard in PTBD and thus 
being preferred over plastic endoprostheses. Metal 
stents have higher patency rates than plastic ones and 
in case of recurrent obstruction a new stent can easily 
be placed in the blocked metal stent, without having 
to remove the old one (as opposed to plastic stents) 
(26). Metal stents are associated with shorter hospital 
stay and lower cost than plastic stents (16,22,23). A 
new development is the use of covered stents, which 
aim at reducing the incidence of recurrent jaundice 
by preventing tumour ingrowth into the stent. 
Although tumour ingrowth is probably prevented 
to some extent by the covering of these stents, it is 
unclear whether clogging is also prevented (3,14,27, 
34). Potential drawbacks of such stents are the 
increased chance of stent migration, occlusion of 
side-branches, when stenting hilar lesions, and 
occlusion of the cystic duct, potentially leading 
to cholecystitis. Another concern is the potential 
lack of costeffectiveness of the use of such stents. 
Currently, there is not enough evidence to support 
the routine use of covered stents in malignant bile 
duct obstruction, although in selected cases these 
may be useful. At least as important as advances 
in PTBD technique are the improvements, which 
are made in pre-procedure planning by imaging 
with ultrasound, computed tomography (CT) and 
magnetic resonance cholangiopancreatography 
(MRCP). Particularly when performing drainage 
and stenting of hilar obstruction, treatment planning 
on the basis of imaging is crucial (10). PTBD should 
never be performed without a proper non-invasive 
evaluation of the biliary tree.
Surgical versus non-surgical biliary drainage
Surgical biliary bypass is often performed when 
exploratory laparotomy for a tumour of the pancreatic 
head region shows unresectability of the tumour. 
Adequate decompression of the biliary tree can be 
obtained by performing a hepatico-jejunostomy 
and a gastric bypass is performed simultaneously. 
This prevents the need for an additional laparotomy 
later in the course of the disease when gastric outlet 
obstruction may develop as a result of local tumour 
progression. However, mortality and morbidity rates 
of this ‘double bypass’ procedure remain considerable, 
as they range from 2% to 5%, and from 17% to 
37%, respectively (24,25,40). Several randomized 
trials compare surgical with non-surgical drainage 
(mostly performed endoscopically) in patients 
with pancreatic head carcinoma (1,15,37). Surgical 
treatment is associated with higher postoperative 
mortality and morbidity rates and a longer hospital 
stay than non-surgical drainage (mostly performed 
endoscopically), but recurrent jaundice requiring 
stent exchange and late duodenal obstruction are 
more common in the non-surgical drainage group 
(15,35). Similarly, a randomized study comparing 
percutaneous biliary drainage with surgical bypass 
in patients with unresectable pancreatic head cancer 
demonstrates successful drainage in all the patients, 
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but there are higher 30-day mortality and procedure-
related mortality as well as a longer hospital stay in 
the surgical group. These advantages of percutaneous 
drainage are partly annihilated by the higher number 
of readmissions for recurrent jaundice and duodenal 
obstruction requiring surgery (4). The endoscopic 
stent placement is more cost-effective than surgical 
biliary drainage, although frequent stent exchanges 
were necessary in the non-surgical group (32). It 
is currently accepted to consider surgical biliary 
drainage only in patients with pancreatic head cancer 
who are in an otherwise good condition and who 
have a life expectancy of more than 6 months (38). 
This means that surgical drainage is only performed 
in patients who undergo an exploratory laparotomy 
and are unresectable. The advent of duodenal stenting 
in addition to biliary stenting may obviate the need 
for surgical treatment of gastric outlet obstruction 
and this may further expand indications for biliary 
stenting in the near future. Currently, prospective 
studies comparing combined biliary and duodenal 
stenting versus surgery are lacking and the results 
of such studies should be awaited (39). A different 
situation occurs in the patients with malignant 
obstruction at the hilum. Patients with Bismuth type 
I and II lesions are surgical candidates. Resection of a 
type III lesion often requires major surgery and only 
a minority of these patients will eventually undergo 
resection. Type IV lesions are generally considered 
to be irresectable. In patients with unresectable 
hilar cholangiocarcinoma, performing a hepatico-
jejunostomy at the hilum is technically difficult and 
associated with higher complication and mortality 
rates than non-surgical stenting (20,29). In addition, 
gastric outlet obstruction is an uncommon sequelae 
of hilar cholangiocarcinoma and surgery for this 
complication is, therefore, only rarely required. 
Thus, non-surgical drainage of the biliary system is 
the preferred treatment option in the vast majority 
of patients with unresectable hilar malignancy (36).
Percutaneous versus endoscopic biliary 
drainage
When comparing percutaneous and endoscopic 
treatment, distal and proximal bile duct obstruction 
should be distinguished again. However, in a two 
prospective randomized trials comparing PTBD and 
endoscopic retrograde cholangiopancreatography 
(ERCP) for palliation of inoperable malignancy 
causing bile duct obstruction, this distinction has not 
been made (17,33). PTBD with self-expanding metal 
stents is compared with conventional endoscopic 
polyethylene endoprostheses (EPE) which reflects 
current practice in most institutions (31). The 
technical success rates of both procedures are 
similar (PTBD, 75% and EPE, 58%; p=0,29), whereas 
therapeutic success is higher in the PTBD group 
(71% versus 42%; p=0,03). Major complications are 
more common in the this group (61% versus 35%; 
p=0,09) but does not account for differences in 30-
day mortality rates (PTBD, 36% and EPE, 42%; 
p=0,83). overall median survival is significantly 
higher in the PTBD group than in the EPE one 
(3,7 versus 2,0 months; p=0,02). In the majority of 
patients (7/11) in whom endoscopic stent placement 
fails, subsequent percutaneous stent placement is 
successful. It is concluded that PTBD with placement 
of a self-expanding metal stent is an alternative to 
placement of an EPE.
Numerous non-comparative studies assessing 
PTBD and ERCP for treatment of distal bile duct 
obstruction suggest that there are no significant 
differences in technical success rates between 
percutaneous and endoscopic treatment (6,7,19). 
Complication and mortality rates are comparable, 
although the type of complications differs. 
Pancreatitis is more often seen after ERCP, whereas 
bile leakage is more frequently seen after PTBD. 
An advantage of ERCP over PTBD is the absence 
of a percutaneous drainage tube, which may be 
uncomfortable for the patient and requires removal 
after several days in most cases. Futhermore, PTBD 
may be painful in some patients, but patient’s 
preference for either technique has not been studied. 
Success and complication rates for both ERCP 
and PTBD depend on the operator’s skills and 
experience and this may influence the choice for one 
of these techniques in different institutions. In most 
centres, ERCP is used as the primary procedure 
for palliative stenting of malignant distal bile duct 
obstruction. Until recently, ERCP is considered an 
important diagnostic tool for assessment of patients 
with malignant distal bile duct obstruction, too. 
Its diagnostic role is now replaced by ultrasound, 
CT, and MRCP almost completely and the only 
diagnostic value of ERCP lies in its ability to obtain 
brush cytology of suspected lesions. In spite of the 
32 Scripta Scientifica Medica, vol. 45, Suppl. 2, 2013, pp. 29-34Copyright © Medical University of Varna
Biliary drainage in obstructive jaundice 
evidence of superior patency of metallic stents, 
plastic endoprostheses are usually inserted during 
ERCP only to be replaced by metallic stents when 
they occlude after short intervals (6,41). As a result, 
frequent stent exchanges are necessary using this 
approach and this may counterbalance the short 
term cost benefit of applying the plastic stents (13,43). 
In current practice, PTBD in distal bile duct 
obstruction is mostly reserved for cases where ERCP 
fails or is impossible. The most common reasons for 
this are duodenal stenosis, failure to pass the biliary 
stricture or to cannulate the papilla (e.g. because 
of its position in a duodenal diverticulum), altered 
anatomy after surgery (B2 stomach), or prior creation 
of a bilioenteric anastomosis. In most of such cases, 
PTBD is technically successful and PTBD use as a 
secondary tool after failure of or inability to perform 
ERCP is widely accepted. In hilar obstruction, the 
situation is less clear and both PTBD and ERCP are 
used as a primary drainage modality in different 
institutions. PTBD has a distinct advantage over 
ERCP in that with ultrasound guidance one or more 
appropriate segments for drainage can be chosen and 
injection of contrast matter in segments too small 
to be drained can be prevented. As stated before, 
ultrasound guidance during PTBD is extremely 
useful in such patients. Furthermore, negotiating 
the hilar strictures and draining the appropriate 
segments can be very difficult with ERCP and 
success rates are lower than for distal strictures (5,8). 
Whether PTBD or ERCP is used as the primary 
tool in patients with hilar obstruction depends on 
specific patient’s circumstances and the referring 
physician’s preference as well as on local availability 
and expertise. As hilar cholangiocarcinoma is 
a relatively rare tumour and both percutaneous 
and endoscopic palliations require considerable 
expertise, it is probably useful to concentrate. 
In conclusion, the technical success of the 
procedure depends on the experience of the 
interventional radiologist performing the drainage. 
It can be as high as nearly 100%. Clinical efficacy is 
usually lower but still over 90%. When endoscopic 
drainage alone fails, a combined percutaneous/
endoscopic procedure should only be performed if it 
can be carried out simultaneously.
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